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TREATMENT WITH CHONDROITIN SULFATE REDUCES CARTILAGE
VOLUME LOSS IN KNEE OA PATIENTS ASSESSED BY MRI: A RANDOMIZED,
DOUBLE-BLIND, PLACEBO CONTROLLED PILOT STUDY
J.-P. Pelletier1 , L.M. Wildi1, J.-P. Raynauld1, A. Beaulieu2, L. Bessette3,
F. Morin4, F. Abram5, M. Dorais6, J. Martel-Pelletier1
1Univ. of Montreal Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada; 2Faculty
of Med., Univ. of Laval, Quebec, QC, Canada; 3Groupe de Recherche en
Rhumatologie et Maladies Osseuses, Sainte-Foy, QC, Canada; 4Ctr. de
Recherche Musculo-squelettique, Trois-Rivières, QC, Canada; 5ArthroVision Inc.,
Montreal, QC, Canada; 6StatSci. Inc., Notre-Dame de l’Île-Perrot, QC, Canada
Purpose: Disease modifying osteoarthritis drug (DMOAD) development re-
mains a challenge. The DMOAD effect of chondroitin sulfate (CS), shown by
a reduction in joint space narrowing (X-ray) in knee OA [1–3], needs to be
further objectiﬁed by quantitative cartilage imaging. The aim of this study
was to determine the effect of CS treatment on the extent of cartilage loss,
subchondral bone marrow lesion (BML) size, and severity of synovitis in pa-
tients with symptomatic knee OA using magnetic resonance imaging (MRI).
Methods: This pilot study was a multicentre, randomized, double-blind,
controlled trial of CS (Condrosan®, Bioiberica, Barcelona, Spain) 800 mg
once daily vs. placebo for 6 months followed by an open label period of 6
months in which patients from both groups received CS 800 mg once daily.
Patients with primary knee OA and clinical signs of synovitis (joint swelling
and/or effusion) were included. MRI was performed at baseline, 6, and 12
months. The cartilage volume was quantiﬁed using 3D reconstruction of
the MR images. The BML size, severity of synovitis, and meniscal extrusion
were assessed on a semi-quantitative scoring system.
Results: 70 patients were enrolled and 62 (88.6%) completed the study.
Baseline characteristics were similar between the two treatment groups
with the exception of age (59.7±9.4, 64.6±9.6 years old [mean±SD],
respectively; p=0.03). Patients receiving CS treatment for 12 months com-
pared to the patients receiving placebo (6 months placebo followed by
6 months CS) experienced a signiﬁcant reduction in cartilage volume
loss in the lateral compartment at 6 (-1.1±3.3%, -3.0±4.5%; p=0.05) and
12 months (-1.0±3.8%, -3.9±4.5%; p=0.013). These differences were even
more pronounced in OA patients without medial meniscal extrusion (6
months, -1.1±3.4%, -3.6±4.3%; p=0.02; 12 months, -1.1±3.8%, -4.3±4.3%;
p=0.008). Patients on CS treatment also presented reduction in BML score
at 6 months and a marked reduction at 12 months (global knee, -0.7±2.6,
0.6±2.1; p=0.06; lateral compartment, -0.4±1.1, 0.7±1.4; p=0.002). No
difference was found in synovitis severity between the 2 treatment groups
at 6 months. Interestingly, the patients in the CS treatment group, who
were receiving concomitant non-steroidal anti-inﬂammatory drug (NSAID)
treatment, demonstrated a statistically signiﬁcant reduction in synovial
membrane thickness compared to the placebo group (1.3±0.3 mm, 1.6±0.3
mm; p=0.03), and a reduction in synovitis score (3.0±1.9, 4.5±1.6; p=0.09),
as well as lower incidence of joint swelling (p=0.09).
Conclusions: CS treatment was found to signiﬁcantly reduce the cartilage
volume loss in knee OA starting as early as 6 months into treatment.
This was associated with a concomitant reduction in BML size supporting
the hypothesis of their role in cartilage volume loss. CS treatment in
combination with NSAIDs also reduced severity of synovitis. These ﬁndings
further support the DMOAD effect of CS and provide new information on
its mode of action on the OA process.
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EFFECTS OF HYLAN G-F 20 [SYNVISC ®] SUPPLEMENTATION ON
CARTILAGE PRESERVATION IN OSTEOARTHRITIS OF THE KNEE: A
TWO-YEAR, SINGLE -BLIND CLINICAL TRIAL
S. Hall, Y. Wang, F. Hanna, A. Wluka, P. Marks, G. Grant, M. Feletar,
F. Cicuttini
Monash Univ., Malvern, Australia
Purpose: To assess the effect of viscosupplementation with hylan G-F 20
on the progression of cartilage loss over two years in patients with knee
osteoarthritis (OA).
Methods: A single-blind, parallel control group pilot clinical trial was
performed in 78 eligible patients with symptomatic knee OA (Kellgren
Lawrence grade II and III). Patients were assigned to either an intervention
group (n=39, receiving four courses (3×2.0cc) of intra-articular HYLAN-G-F
20 injections at six months intervals or a control group (n=39, without
injections but receiving usual care for OA). Magnetic resonance imaging
the target knee was performed at baseline, 6, 12, and 24 months and
images were analysed blinded both to patient group and sequence Tibial
cartilage volume, tibiofemoral cartilage defects and bone marrow lesions
were assessed at baseline and follow up
Results: 55 subjects (71%) completed 2-year follow up. There was no
signiﬁcant difference in age, gender, BMI, baseline cartilage volume, bone
marrow lesions and bone area in those who completed and those who did
not (all P>0.13). Analysis of completers demonstrated a signiﬁcantly re-
duced annual percentage rate of medial, lateral and total tibial cartilage loss
in the intervention group (mean±SD, -0.3±2.7%, -1.4±4.3% and -0.5±2.3%)
compared with the control group (2.3±2.6%, 1.4±2.6%, 1.6±1.8%, P=0.001,
0.005 and 0.001 for difference, respectively). The intervention group also
showed a signiﬁcant reduction in the increase of cartilage defect score
in the medial and total tibiofemoral compartments (0.1±1.3 and 0.5±2.0)
compared with the control group (0.8±1.5 and 1.6±2.0, all P=0.05). There
was no signiﬁcant difference of change in bone marrow lesions between
the intervention and control groups.
Conclusions: 6 monthly intra-articular injections of HYLAN-G-F 20 ad-
ministered without regard to symptoms have a beneﬁcial effect on knee
cartilage preservation as measured by both cartilage volume and cartilage
defect score. Over two years, the control group continues to lose cartilage
while there is no signiﬁcant loss of cartilage in the HYLAN G-F treated
group. HYLAN G-F 20 could be further evaluated in larger trials as a possible
disease-modifying agent in patients with knee OA.
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EFFICACY OF DIETING OR EXERCISE VS. CONTROL IN OBESE KNEE
OSTEOARTHRITIS PATIENTS AFTER A CLINICALLY SIGNIFICANTWEIGHT
LOSS: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL
R. Christensen, A.R. Leeds, S. Lohmander, B.F. Riecke, P. Christensen,
T.J. Sørensen, H. Gudbergsen, J. Aaboe, M. Henriksen, M. Boesen, A. Astrup,
H. Bliddal
The Parker Inst., Copenhagen, Denmark
Purpose: Patients with knee osteoarthritis, who are overweight, should be
encouraged to lose weight and maintain their weight at a lower level; basic
therapy includes reduction in weight in the obese and exercises to keep in
shape.
Our objective was to compare the symptomatic eﬃcacy of 1-year dieting
or exercise vs. control in obese patients after a clinically signiﬁcant weight
loss. We hypothesised that a continued dietary program rather than an
exercise regimen with the same amount of attention should maintain a
clinically signiﬁcant weight loss in obese patients with knee OA.
Methods: Obese individuals (>50 years) having knee OA (ACR criteria), and
motivated for weight loss, were enrolled in a 16-week course, provided a
very-low energy formula diet for 8-weeks and 8 weeks on normal hypo-
energetic foods. They were then randomised to either 1-year maintenance
program with [D] continuous dietary consultations, or [E] exercise pro-
grams lead by a physiotherapist, or [C] a control group receiving no support
from the project team for 1 year. The amount of attention was exactly
the same in D and E, preventing performance and detection bias. The pri-
mary endpoint was the number of patients fulﬁlling the OMERACT-OARSI
response criteria. The statistical analyses were based on a non-responder
intention-to-treat population (baseline observation carried forward); i.e. all
patients enrolled in the ﬁrst 16-weeks. Analyses were based on 1-factor
ANCOVA adjusting for baseline and absolute risk differences following 2×2
(chi-square) contingency tables.
Results: 192 participants, mean age 63 years (SD 6), mean weight 103.2 kg
(15.0), and BMI of 37.3 (4.8) were randomized (1:1:1; 64 patients in each
group). As illustrated in the ﬁgure, mean weight losses following 16-weeks
initiating weight loss and 1 year on either D, E, and C were 10.9, 6.3, and 8.2
kg, respectively (ANCOVA: P=0.003) at week 68; D lost signiﬁcantly more
weight than did E: 4.6 (95%CI 2.0, 7.3; P<0.001). The primary outcome
- the number of patients having an OMERACT-OARSI response at week
68 in the D, E, and C groups were 30 (47%), 24 (38%), and 30 (47%),
respectively (P=0.47); apparently with no signiﬁcant difference between
D and E, with an absolute difference of 8.7% (-7.7, 26.4%; P=0.77). There
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were no statistically signiﬁcant group differences for any of the secondary
patient-reported outcomes at week 68.
Conclusions: A signiﬁcant weight reduction improves the knee OA patients’
symptoms, as a high proportion of patients experience an OMERACT-OARSI
response at 16 weeks. However, although the sustainability of weight loss
was signiﬁcantly better in the diet group, this trial did not provide any
evidence of a difference between continuous attention from a dietician
following a 1-year maintenance program compared to either exercise or
‘nothing’ in terms of treating OA symptoms.
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A MULTICENTRE, INTERNATIONAL, DOUBLE BLIND, RANDOMIZED,
PLACEBO - CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF
2 DIFFERENT REGIMENS OF HYADD4-G IN KNEE OSTEOARTHRITIS
K. Pavelka1, F.U. Niethard2, N. Giordan3
1Inst. of Rheumatology, Prague 2, Czech Republic; 2Univ.sklinik und Poliklinik
der RWTH, Aachen, Germany; 3Fidia Farmaceutici SpA, Padova, Italy
Purpose: Hyaluronic acid (HA) has been included in European League
Against Rheumatology, Osteoarthritis Research Society International, Amer-
ican College of Rheumatology, American Pain Society and American
Academy of Orthopedic Surgeons recommendations for treatment of
painful knee osteoarthritis (OA). Intra-articular (IA) sodium hyaluronate
has proven eﬃcacious and well tolerated for the treatment of pain as-
sociated with knee OA, but optimal molecular weight of HA and dosing
regimen is still not known. HYADD4-G is a novel hydrogel obtained with a
new linear (not cross- linked) derivative of HA of bacterial origin (partial
hexadecylamide of 500-730 kDa hyaluronic acid Pat. No. EU 1095064) that
shows higher viscoelastic properties than the native HA with preservation
of hyaluronan biocompatibility.
The study objective was to evaluate the eﬃcacy and tollerability of 2
different HYADD4-G dosing regimens (2 versus 3 i.a. injections) against
phosphate-buffered saline (PB-Saline) up to 6 months in patients with knee
OA.
Methods: Prospective, multicentre, parallel, randomized, double-blind
(masked observed), PB-Saline controlled, 6 months study in knee OA.
Patients: primary knee OA according to ACR criteria, Kellgren-Lawrence
II-III stage, pain on walking >40 mm on VAS at baseline. Primary outcome
measure: pain during 50 ft (15 m) walk test, measured by Visual Ana-
logue Scale (VAS) at visits 2-9. Statistical Analysis: eﬃcacy evaluated in
intent-to-treat (ITT) population. Two-sided superiority tests of 2 different
regimens of HYADD4-G vs PB-saline for all primary and secondary outcome
measures.
Results: A total of 439 patients were randomized either to HYADD4-G 2 inj.
group (n=145), HYADD4-G 3 inj. (n=150) and PB-saline (n=144). There were
no signiﬁcant differences in demographic and disease activity parameters
between groups at baseline. Symptomatic outcome measures showed a
signiﬁcant improvement from baseline in the three treatment groups. In
particular, considering the HYADD4-G 2 injections group, the mean change
(%) between baseline and ﬁnal visit for the 50 ft walk test (VAS) was -36,5
mm (-58,9%), for WOMAC pain -19,8 mm (-40,4%), for WOMAC Stiffness
-20,5 mm (-27,1%), and for WOMAC physical function -18,2 mm (-35,4%).
However, due to a huge and unexpected placebo response, for primary and
secondary endpoints, no statistically signiﬁcant differences between the
treatment groups at any of the Visits 5 to 9 were observed. In exploratory
sub-group analysis of patients with age <65 years the pain in the target
knee was improved from baseline Visit 2 to Visit 5 in all treatment groups.
The comparison regarding pain in the target knee during walk test between
the HYADD4-G 2 injections group and the PB-Saline group for patients <65
years revealed the following p-values: P=0,1561 at the ﬁrst visit after the
last injection (day 28), P=0,0267 at day 60, P=0,0397 at day 90, P=0,0499 at
day 120, and P=0,3329 at day 180 (2-sided t-test).
There were no clinically relevant and/or statistically signiﬁcant differences
between the treatment groups with regard to frequency, distribution, inten-
sity, premature termination, or seriousness, but for probable relationship
to study group and occurrence of AEs in target knee.
Conclusions: New HA formulations HYADD4-G were effective and well
tolerated in symptomatic treatment of painful knee OA. The reductions in
VAS knee pain for patients <65 years were signiﬁcantly more effective in
HYADD4-G given in a 2 IA injections than PB-saline. A clinically signiﬁ-
cant decrease in analgesic consumption, was also observed in the same
HYADD4-G study group.
Keywords: osteoarthritis, hyaluronic acid, IA therapy.
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EFFICACY AND SAFETY OF 2 PROPRIETARY BASED CHONDROITIN
SULPHATE MEDICINAL PRODUCTS: STRUCTUM® 1000MG (500 MG BID)
AND CHONDROSULF® 1200MG (400 MG TID) IN 837 PATIENTS WITH
SYMPTOMATIC KNEE OSTEOARTHRITIS (KOA)
P. Fardellone1, M. Zaim2, E. Maheu3, A.-S. Saurel2
1Rhumatology Dept., CHU Amiens, Amiens, France; 2Inst. de Recherche Pierre
FABRE, Ramonville Saint-Agne, France; 3Rhumatology Dept., St Antoine
Hospital, Paris, France
Purpose: To compare the eﬃcacy and safety of 2 proprietary based Chon-
droitin Sulphate medicinal products: Structum® 1000mg and Chondrosulf®
1200mg.
Methods: Multicentre, randomized, double-blind, double placebo, active
controlled, parallel-group study, conducted according to a non-inferiority
design. Patients aged 50-80 years with symptomatic KOA (ACR criteria)
were randomized to receive during 24 weeks either Structum 500mg BID
or Chondrosulf 400mg TID. Inclusion criteria were: global pain in the
target knee ≥ 40 mm on a 100-mm visual analog scale (VAS), Lequesne’s
Algofunctional Index (LFI) score > 7 (range: 0-24) and radiological Kellgren-
Lawrence grade 2 or 3. The primary outcome was the mean variation over
24 weeks of the global pain (VAS) and LFI score. Main secondary outcomes
were patient’s and physician’s global assessments, Omeract-OARSI respon-
ders rate, concomitant analgesics intake and quality of life (SF-12). Safety
was assessed by recording any adverse events (AE). A non-inferiority test
was performed: 95% conﬁdence interval (CI) of the difference Structum -
Chondrosulf on change of VAS and LFI scores. Predeﬁned non inferiority
limit was settled as the lower limit of the 95% CI above -5mm and -1pt
respectively for VAS and LFI scores.
Results: 837 patients were randomized: 817 analyzed in the full analysis
dataset (FAS), 692 in the per protocol (PP) analysis with no difference be-
tween groups at entry regarding demographics and disease characteristics.
The main eﬃcacy analysis (PP) showed no difference between the 2 groups
on the mean variations of pain VAS or LFI scores over 24 weeks which
varied for VAS and LFI scores by -23,9 (17,5) and -3,2 (2,4) respectively in
Structum group and by -23,8 (17,2) and -3,1 (2,4) in Chondrosulf group.
Differences for VAS and LFI were respectively 0.01 [IC95%: -2,6; 2,6] and
0,139 [IC95%: -0,2; 0,5]. The lower limit of the 2 CI were above the prede-
ﬁned non inferiority margins (-5 and -1 respectively), clearly demonstrating
the non inferiority of Structum compared to Chondrosulf. The analysis on
the FAS gave similar results. Analyses of the secondary eﬃcacy outcomes
(PP and FAS) populations showed the same trends for each treatment
with improvements of clinical relevance at W24. The overall improvement
